Jura Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Jura Bio, Inc. - overview
Established
2017
Location
Boston, MA, US
Primary Industry
Pharmaceuticals
About
Based in Massachusetts, US, and co-founded by Elizabeth Wood (CEO), Julie Norville (CSO/CTO), and George Church (SAB Chair) in 2019, Jura Bio, Inc. operates as a pharmaceutical company offering autoimmune disease therapy solutions. In September 2023, the firm raised USD 16. 1 million in venture funding led by investor Fontus Capital.
The company engages in the development of genomic medicine and expanding the scope of immune-mediated medicines. With a focus on cancer and T-cell mediated autoimmune diseases, JURA Bio has introduced different solutions such as MHC-CAR and cell-free systems. These innovations open new avenues for targeted therapies, harnessing the power of TCR therapies to combat cancer and control the immune response in autoimmune diseases. Additionally, the firm also employs an ML-guided end-to-end discovery and development platform that seamlessly integrates synthetic biology and machine learning.
This platform enables the design, construction, and testing of protein-based therapies at an unprecedented scale. The company plans to utilize the September 2023 funding to expand its machine learning-based pharmaceutical research.
Current Investors
Fontus Capital
Primary Industry
Pharmaceuticals
Sub Industries
Bioinformatics, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.jura.bio/
Verticals
Artificial Intelligence, HealthTech, Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.